Menopausal Hormone Therapy

• Menopausal Hormone Therapy (MHT) replaces hormones like estrogen and progestin to manage menopausal symptoms.
• MHT comes in various forms, including systemic (pills, patches) and local (vaginal creams), and can be estrogen-only or combined with progestin.
• Benefits include significant relief from hot flashes, night sweats, and vaginal dryness, as well as protection against osteoporosis.
• Potential risks, such as blood clots, stroke, and certain cancers, vary based on age, health, and type of therapy.
• Decisions regarding MHT should always be made in consultation with a healthcare provider to weigh individual benefits against risks.

What is Menopausal Hormone Therapy (MHT)?

Menopausal Hormone Therapy (MHT) refers to a treatment that replaces hormones, primarily estrogen, that a woman’s body stops producing during menopause. The primary goal of MHT is to alleviate bothersome menopausal symptoms such as hot flashes, night sweats, vaginal dryness, and mood changes, which can significantly impact quality of life. For women with an intact uterus, estrogen is typically prescribed along with progestin to protect the uterine lining from potential overgrowth (endometrial hyperplasia) and cancer.

The approach to MHT has evolved over time, with current guidelines emphasizing individualized treatment based on a woman’s symptoms, medical history, and personal preferences. It is generally recommended to use the lowest effective dose for the shortest duration necessary, particularly for systemic therapy, to manage symptoms effectively while minimizing potential risks. MHT can be a highly effective option for many women experiencing severe menopausal symptoms.

Types of Menopausal Hormone Therapy

The **types of menopausal hormone therapy** are diverse, catering to different needs and symptom profiles. These therapies can be broadly categorized by the hormones they contain and their method of delivery. Understanding these distinctions is crucial for personalized treatment.

• Estrogen-only Therapy (ET): This type is prescribed for women who have had a hysterectomy (surgical removal of the uterus). It involves only estrogen, as there is no uterine lining to protect.
• Estrogen-progestin Therapy (EPT): Also known as combined hormone therapy, EPT is for women who still have their uterus. The progestin component is essential to counteract the effects of estrogen on the uterine lining, preventing endometrial hyperplasia and reducing the risk of uterine cancer.
• Systemic Hormone Therapy: This refers to MHT that delivers hormones throughout the bloodstream to treat widespread menopausal symptoms. It is available in various forms:
  • Pills (oral)
  • Patches (transdermal)
  • Gels and sprays (topical)
• Local Hormone Therapy: This type delivers estrogen directly to the vaginal area to treat localized symptoms like vaginal dryness, itching, burning, and painful intercourse (genitourinary syndrome of menopause). It comes in forms such as:
  • Vaginal creams
  • Vaginal rings
  • Vaginal tablets

  Local therapy typically uses much lower doses of estrogen, resulting in minimal systemic absorption.

Benefits and Risks of Menopausal Hormone Therapy

Weighing the **benefits of menopausal hormone therapy** against its potential **risks of menopausal hormone therapy** is a critical discussion between a woman and her healthcare provider. For many women, MHT offers significant relief from debilitating menopausal symptoms. The primary benefits include effective reduction of hot flashes and night sweats, improvement in sleep quality, and alleviation of vaginal dryness and related discomfort. MHT is also highly effective in preventing bone loss and reducing the risk of osteoporosis-related fractures, a significant concern for postmenopausal women. According to the World Health Organization (WHO), osteoporosis affects approximately 10% of women aged 60-70 and 20% of women aged 80 or more globally, highlighting the importance of preventative measures.

However, MHT is not without risks. The risks can vary depending on a woman’s age, time since menopause onset, and the type of therapy used. Potential risks associated with systemic MHT include an increased risk of blood clots (deep vein thrombosis and pulmonary embolism), stroke, and, for women using combined estrogen-progestin therapy, a slightly increased risk of breast cancer. The risk of heart disease can also be a concern, particularly if MHT is initiated many years after menopause onset or in older women. It is crucial for individuals to have a thorough medical evaluation to determine if MHT is appropriate for their specific health profile, considering their personal and family medical history.